Phibro Animal Health (NASDAQ:PAHC) Trading Down 5% on Insider Selling

Phibro Animal Health Corporation (NASDAQ:PAHC)’s stock price dropped 5% during mid-day trading on Friday following insider selling activity. The stock traded as low as $40.58 and last traded at $39.5260. Approximately 9,657 shares traded hands during trading, a decline of 95% from the average daily volume of 184,352 shares. The stock had previously closed at $41.61.

Specifically, CEO Jack Bendheim sold 13,158 shares of the business’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $41.98, for a total transaction of $552,372.84. Following the sale, the chief executive officer directly owned 18 shares in the company, valued at approximately $755.64. The trade was a 99.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Jack Bendheim sold 14,687 shares of the company’s stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $41.68, for a total transaction of $612,154.16. Following the completion of the sale, the chief executive officer directly owned 29,838 shares of the company’s stock, valued at approximately $1,243,647.84. This represents a 32.99% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. boosted their target price on Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday, December 29th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Phibro Animal Health presently has an average rating of “Hold” and an average target price of $31.40.

Phibro Animal Health Trading Down 6.2%

The company’s 50-day moving average is $40.16 and its 200 day moving average is $37.47. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32. The firm has a market cap of $1.58 billion, a PE ratio of 23.50, a P/E/G ratio of 1.18 and a beta of 0.79.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.15. The company had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health had a net margin of 4.85% and a return on equity of 36.26%. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. As a group, sell-side analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were paid a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s payout ratio is 28.92%.

Institutional Trading of Phibro Animal Health

Hedge funds have recently made changes to their positions in the stock. Tudor Investment Corp ET AL increased its stake in Phibro Animal Health by 3.4% in the 3rd quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after buying an additional 338 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Phibro Animal Health by 2.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 13,005 shares of the company’s stock valued at $332,000 after acquiring an additional 363 shares in the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Phibro Animal Health by 113.2% during the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after acquiring an additional 386 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Phibro Animal Health by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock worth $260,000 after acquiring an additional 546 shares during the last quarter. Finally, Prospera Financial Services Inc raised its holdings in shares of Phibro Animal Health by 3.6% during the second quarter. Prospera Financial Services Inc now owns 19,910 shares of the company’s stock worth $508,000 after acquiring an additional 690 shares in the last quarter. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.